Breast Cancer Trial, Recruiting NCT05658341 Sponsor: Siel Bleu Condition: Breast Cancer
Back to Breast Cancer

Breast Cancer Trial, Recruiting

NCT05658341
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • Women between 18 and 72 years of age
  • People who have been diagnosed with localised breast cancer of any type, and who have either finished their main treatments (such as surgery, chemotherapy, or radiotherapy) within the last 15 months, or are still undergoing hormone therapy, or are nearing the end of their Herceptin treatment
  • People who speak French
  • People who are covered by the French Social Security system or a similar health insurance arrangement

Who may not be able to join:

  • People who have a cancer diagnosis other than breast cancer, or whose breast cancer has come back or spread to other parts of the body
  • People whose doctor has advised against exercise for medical reasons (a medical certificate confirming that physical activity is not medically contraindicated will be required)
  • People with significant vision, hearing, or behavioural difficulties that would make it hard to take part in group physical activity sessions
  • People who have plans to move away from the area where the trial is based
  • People who are already taking part in another clinical trial
  • People who are male

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 8 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Gwenn Menvielle, PhD, Institut National de la Santé Et de la Recherche Médicale, France

Phone: 0033607129986

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Sponsor
Siel Bleu
Registry
ClinicalTrials.gov
Start date
6 November 2023
Est. completion
1 January 2026

Where this trial is recruiting

🇫🇷 France

Primary endpoints

Health-related quality of life

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 8 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov